|
Sign In to gain access to subscriptions and/or personal tools.
|
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride
Cindy J Rubin
Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey, US.
Jean-Marie Ledeine
Bristol-Myers Squibb, Braine-l'Alleud, Belgium.
Fred T Fiedorek
Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey, US.
The efficacy and safety of muraglitazar versus glimepiride were evaluated in patients with type 2 diabetes. After open-label metformin monotherapy, 1,805 patients received randomised therapy with muraglitazar 2.5 mg or 5 mg or with glimepiride 1 mg in a doubleblind 52-week study. The primary end point was change in glycosylated haemoglobin (HbA1C); secondary end points were changes in fasting lipid levels and glycaemic indices.
At week 52, the reduction in HbA1C with muraglitazar 5 mg plus metformin was superior (p<0.0001) and with muraglitazar 2.5 mg it was non-inferior in comparison with glimepiride. At week 12, muraglitazar significantly decreased triglyceride levels (p<0.0001) and increased levels of high-density lipoprotein cholesterol (HDL-C) (p<0.0001). Oedema, weight gain and heart failure were more evident with muraglitazar. Muraglitazar 5 mg plus metformin significantly improved HbA1C, triglyceride and HDL-C levels in patients with type 2 diabetes. Cardiovascular events were similar among groups ( 2%), but there was an imbalance of total mortality in favour of glimepiride.
References
- 1. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21:160–78.[Abstract]
- 2. Haffner SM, American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68–S71.[CrossRef][Medline]
[Order article via Infotrieve]
- 3. Robins SJ Rubins HB, Faas FH et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513–17.[Abstract/Free Full Text]
- 4. Turner RC Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–12.[Abstract/Free Full Text]
- 5. Kersten S Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421–4.[CrossRef][Medline]
[Order article via Infotrieve]
- 6. Kota BP Huang TH-W, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005;51:85–94.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 7. Buse JB Rubin CJ, Frederich R et al. Muraglitazar, a dual (
 / ) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther 2005;27:1181–95.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve] - 8. Kendall DM Rubin CJ, Mohideen P et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (/) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006;29:1016–23.[Abstract/Free Full Text]
- 9. Berger JP Akiyama TE, Meinke TP. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005;26:244–51.[CrossRef][Medline]
[Order article via Infotrieve]
- 10. Nesto RW Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256–63.[Free Full Text]
- 11. Guan Y Hao C, Cha DR et al. Thiazolidinediones expand body fluid volume through PPAR stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861–6.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 12. Advisory Committee briefing document: PargluvaTM (muraglitazar, BMS-298585). Available at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4169B2_01_01-BMS-Pargluva.pdf. (Accessed April 10, 2008.)
- 13. Labriola D, Viraswami-Appanna K, Rubin C et al. Adverse cardiovascular events observed with muraglitazar in type 2 diabetes: a meta-analysis. Available at: http://www.clinicalstudyresults.org/drugdetails/?drug -name_id=450&sort=c.company_name&page=1&drug_id=2109. (Accessed April 21, 2008.)
- 14. Nissen SE Wolski K, Topol JE. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581–6.[Abstract/Free Full Text]
- 15. EI Hage, J. Available at: http://www.fda.gov/ohrms/dockets/ac/05/slides/2005–4169S2_02_02-FDA-EIHage.ppt. (Accessed April 10, 2008).
- 16. Discontinuation of tesaglitazar development. Available at: http://www/ astrazeneca.com/pressrelease/5240.aspx, AstraZeneca (2006–05–04). (Accessed April 10, 2008.)
- 17. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86.[Abstract/Free Full Text]
Diabetes and Vascular Disease Research, Vol. 5, No. 3,
168-176 (2008)
DOI: 10.3132/dvdr.2008.028
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. J. Rubin, K. Viraswami-Appanna, and F. T. Fiedorek
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes
Diabetes and Vascular Disease Research,
July 1, 2009;
6(3):
205 - 215.
[Abstract]
[PDF]
|
|
|
|
|
